NCT07318480 Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
| NCT ID | NCT07318480 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Cocaine Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-02-25 |
| Primary Completion | 2030-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-02-25 with a primary completion date of 2030-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers will test whether cognitively enhanced transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex can reduce craving in inpatients with cocaine use disorder. Neuroimaging before and after stimulation will establish the neural correlates of recovery and allow predictions of outcomes, which will be assessed throughout the study and one month after its completion. Results could pave the way towards development of a new self-administered intervention to reduce craving when it is needed the most, enhancing recovery real-time and in the natural environment in people with cocaine addiction as generalizable to other drugs of abuse and other disorders of self-control.
Eligibility Criteria
Inclusion Criteria: * Ability to understand and give informed consent * Men and women 18-60 years of age. * For women of childbearing potential, current use of a medically acceptable form of birth control * DSM-5 diagnosis of stimulant use disorder with crack/cocaine as the drug of choice Exclusion Criteria: * Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, or delusional disorder as confirmed by the MINI or autism spectrum disorder as confirmed by medical history at the screening visit * Current clinically significant or unstable medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, infectious diseases common in people with substance use disorders including Hepatitis B and C or HIV/AIDS; use of medications deemed exclusionary by the study team; or any laboratory value outside the reference range that the senior investigator team considers to be of clinical relevance * Head trauma with loss of consciousness (\>30 min) * History of neurological or developmental disease of central origin including stroke, brain tumor or seizures, encompassing those symptoms associated with periods of drug withdrawal or abstinence * Metal implants or devices that may be impacted by the electrical stimulation and additional MR contraindications * Women of childbearing potential must use a medically acceptable birth control method during the study and will be asked to take a pregnancy urine test before exposure to tDCS (or MRI)
Contact & Investigator
Rita Goldstein, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT07318480 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Cocaine Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07318480 currently recruiting?
Yes, NCT07318480 is actively recruiting participants. Contact the research team at NARC@mssm.edu for enrollment information.
Where is the NCT07318480 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07318480 clinical trial?
NCT07318480 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Rita Goldstein, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 120 participants.